Updates
Here you’ll find the latest headlines from our project. Stay up to date on our latest news items.
Join Online: VITAL Symposium
VITAL Symposium November 7th
WP1: Manuscripts in the making
WP2: Biomarkers of vaccine responses
WP3’s Final Phase
WP5: Proposal & Plan
Effectiveness of educational interventions for healthcare workers on vaccination dialogue with older adults: a systematic review
Journal title
Pre-vaccination immunotypes reveal weak and robust antibody responders to influenza vaccination
Frailty prevalence in 42 European countries by age and gender: development of the SHARE Frailty Atlas for Europe
Work Package 5 Update September 2023
Work Package 4 Update September 2023
Work Package 3 Update September 2023
Work Package 2 Update September 2023
Work Package 1 Update September 2023
VITAL Holds General Assembly 2023
VITAL Holds Webinar on ‘Ageing and the germinal centre response to vaccination’
Season’s Greetings & Looking Towards the Future
WP5 Update November 2022
WP4 Update November 2022
WP3 Update November 2022
WP2 Update November 2022: Frailty is related to inflammageing markers in the blood
WP1 Update November 2022
WP3 Presentation at ISPOR Europe 2022
Identification of aging-associated immunotypes and immune stability as indicators of post-vaccination immune activation
VITAL Brochure
VITAL Flyer
VITAL Infographic
Work Package 2 update: Vaccine responder profiles in the VITAL vaccination study
Update Work Package 4
Work Package 1: Update
VITAL Presentation at GSK’s global vaccines R&D Days
Work Package 3 study update
Interview Debbie van Baarle for Horizon Magazine
Update on Work Packages
Young & Vital
Update Work Package 2, Frailty in the VITAL Cohort
Daniel Larocque, New Management Board Member
Using qualitative research to develop an elaboration of the TIDieR checklist for interventions to enhance vaccination communication: short report
Expansion and Continuition – Update Work Package 3 (WP3)
Retrospective & Prospective Study – Update Work Package 1 (WP1)
Contact
You can contact us by using the contact form here.
The VITAL project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 806776. The JU receives support from the European Union’s Horizon 2020 research and innovation programme and EFPIA.